CGEM · Cullinan Therapeutics Inc
United States · RS rating 34 · As of 2026-10-14
| Price | 13.64 USD |
|---|---|
| 1-day change | -3.3% |
| RS rating (overall / 1M / 3M / 12M) | 34 / 5 / 22 / 93 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 26 / 33 / 5 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +40.6% |
| Market cap (USD) | $783.8M |